Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing
Bonerge's 12-week, quadruple-blind study evaluates how Urolithin A and Fisetin influence sleep via metabolic and epigenetic biomarkers.
Share
This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: Urolithin A alone, Fisetin alone, Urolithin A + Fisetin combination, and placebo control. The 12-week intervention represents the first systematic evaluation of Urolithin A's potential to resynchronize circadian rhythms and mitigate age-related sleep disturbances.
Key Study Design Features:
Inclusion Criteria: Targets subclinical individuals with impaired sleep quality (PSQI score >5) but no pathological diagnosis, excluding those dependent on caffeine/alcohol.
Multidimensional Assessment:
Subjective: Sleep quality scores, chronotype questionnaire, daytime dysfunction scales.
Objective: Continuous actigraphy monitoring, polysomnography (PSG) analysis.
Biomarkers: NAD+ levels, DNA methylation age, inflammatory markers (IL-6, TNF-α), cortisol rhythm, circadian proteins (BMAL1, PER2), insulin resistance (HOMA-IR), immunoglobulin levels.
"We aim to uncover the causal link between sleep disorders and ageing using epigenetic clocks and metabolic markers, beyond just tracking sleep duration," stated Professor Chen, the lead investigator. "Combining Urolithin A, a circadian regulator, with the senolytic Fisetin explores synergy for novel solutions, like menopausal sleep issues."
Scientific Commitment: Building a Health Ecosystem
As a leading high-quality ingredient producer, Bonerge's R&D follows a pipeline of 'ingredient science, mechanistic research, clinical translation'. The company is actively seeking global clinical partners from academia and industry to explore Urolithin A's potential in sleep health and cellular ageing intervention.
Amidst the anti-ageing industry's shift from consumerism to scientific rigor, Bonerge positions Urolithin A not just as a standalone ingredient, but as a catalyst for evidence-based solutions. Focused on core mechanisms like cellular senescence, Bonerge develops innovative ingredients targeting cellular health, forming a robust "health ecosystem." Key components include:
Fisetin: Potent senolytic selectively clearing senescent cells and reducing their formation, retarding aging in skin, ovarian, and neural tissues.
Urolithin A: Regulates circadian rhythms, boosts endogenous NAD+ synthesis, enhances cellular repair, and improves sleep quality and reproductive health.
L-Ergothioneine: Unique antioxidant with a dedicated transporter (OCTN1), accumulating in high-stress tissues to neutralize ROS, protecting DNA and telomeres.
PQQ Disodium: Activates the PGC-1α/PPARγ pathway, driving mitochondrial DNA replication and biogenesis.
S - Equol: Natural, non-steroidal estrogenic metabolite with high affinity for ERβ, offering a safer alternative for menopause health.
About Bonerge
Bonerge firmly contends that the future of anti-ageing hinges on evidence-based solutions. These solutions are grounded in well-defined biological mechanisms, supported by robust scientific data, and tailored to precise applications, ultimately delivering comprehensive, science-validated health benefits. For more detailed information about our clinical findings, discover more about us at http://www.bonerge.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Lanier Law Firm Representing Health Choice Alliance in Litigation Alleging Eli Lilly Offered Kickbacks to Texas Health Care Providers
MARSHALL, Texas--(BUSINESS WIRE)--Texas Attorney General Ken Paxton has filed a lawsuit in state court against Eli Lilly and Co., accusing the pharmaceutical giant of bribing and inducing medical providers to prescribe its most profitable drugs. In return, physicians were offered unlawful payments and a range of free services in violation of state law. 'This scheme corrupted medical decision-making by giving doctors quid pro quo services obviously intended to influence prescribing,' says Mark Lanier of The Lanier Law Firm. Texas is intervening in the litigation as a plaintiff with the Health Choice Alliance, a research organization jointly represented by The Lanier Law Firm and McKool Smith PC. The lawsuit, filed in Harrison County, accuses Eli Lilly of offering the kickbacks to steer providers to write prescriptions for as many as 14 high-demand drugs such as the GLP-1 medications Mounjaro and Zepbound, resulting in millions of dollars in claims to the state's Medicaid program. Because those charges resulted from Eli Lilly's suspect marketing and service arrangements, the lawsuit claims the practice violated the Texas Health Care Program Fraud Prevention Act and Texas Anti-Kickback Statute. 'This scheme corrupted medical decision-making by giving doctors quid pro quo services obviously intended to influence prescribing,' says Mark Lanier of The Lanier Law Firm. 'As a result, Texas Medicaid became responsible for millions of dollars in improper payments. This case should serve as a warning to the other pharmaceutical giants that such unlawful activities will be investigated and prosecuted.' The lawsuit states that the company provided free nursing services to patients who were prescribed Eli Lilly drugs and offered a supposedly independent web-based service that was in fact managed by Eli Lilly to direct patients to the desired drugs. In addition, the kickbacks involved free services to physicians to obtain insurance authorizations and authorization from Texas Medicaid on behalf of patients, a time-consuming process with administrative costs that are not normally reimbursable to the provider. 'Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,' said Attorney General Paxton in announcing the lawsuit. 'Eli Lilly fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people's health. I will not stand by while corporations unlawfully manipulate our healthcare system to line their own pockets.' The case is Texas vs. Eli Lilly & Co Inc., filed in the 71st District Court of Harrison County, Texas. About The Lanier Law Firm For more than 30 years, the men and women at The Lanier Law Firm have worked tirelessly, throughout the United States, to find unique and effective solutions for their clients. More than 50 skilled attorneys practice law in a broad array of areas, including business litigation, pharmaceutical litigation, asbestos exposure, oil and gas litigation, personal injury as well as defective and dangerous products, among others. Named an Elite Trial Law Firm by The National Law Journal, The Lanier Law Firm has offices in Houston, New York, and Los Angeles.
Business Wire
2 hours ago
- Business Wire
CILA Therapeutics Awarded NCATS Grant to Advance a Transformational Platform That Significantly Enhances Inhaled Delivery of RNA-LNP Into Lung Cells
BOSTON--(BUSINESS WIRE)-- CILA Therapeutics has been awarded a competitive grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to advance the development of its proprietary CIL-Key™ platform — a novel, gene-agnostic delivery technology that significantly and reproducibly enhances the transfection efficiency and delivery of inhaled RNA-loaded lipid nanoparticles (RNA-LNPs) into lung epithelial cells. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine," said Safia Rizvi, CEO, CILA Therapeutics Share In preclinical studies, the CIL-Key™ platform (also referred to as CIL-0X in the grant) achieved up to a 430% increase in delivery of functionally intact RNA into human bronchial epithelial cells cultured at an air-liquid interface (ALI), demonstrating utility across multiple RNA-LNP formulations. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine,' said Safia Rizvi, CEO of CILA Therapeutics. CIL-Key™ is designed to enable efficient, localized intracellular delivery of RNA-based modalities while minimizing systemic exposure. The platform could offer significant advantages for companies developing inhaled RNA therapies and vaccines for a broad range of lung diseases, including Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), COPD and Pulmonary Fibrosis, as well as respiratory infections including influenza, RSV and COVID-19. Chronic pulmonary diseases affect more than 34 million people in the U.S. and more than 545 million globally. These often progressive, life-limiting conditions have a significant impact on quality of life and a high economic burden, creating an urgent demand for novel, effective and easy-to-administer treatments like those powered by CIL-Key™. About CILA Therapeutics CILA Therapeutics is a biotechnology company focused on improving lung health through transformative, scalable, accessible therapies and technologies that easily integrate into patients' daily lives. Its vision is to empower people with pulmonary diseases to breathe easily and live fully. CILA's pipeline includes first-in-class inhaled therapeutics and CIL-Key™, a proprietary platform to enhance delivery of RNA-based therapeutics and vaccines targeting a wide spectrum of pulmonary diseases. Visit CILA is actively seeking strategic partnerships to expand the platform's application across diverse RNA-based pipelines for rare and common pulmonary indications.
Yahoo
2 hours ago
- Yahoo
RAM Technologies' Rapid Growth Earns National Recognition on Inc. 5000 List
PHILADELPHIA, August 14, 2025--(BUSINESS WIRE)--RAM Technologies, Inc., a leading technology enabled services provider to Medicare Advantage, Special Needs and Managed Medicaid health plans, has earned a place on the 2025 Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. With three-year revenue growth of nearly 100%, this marks the company's ninth time on the list. The Inc. 5000 offers a data-driven look at the nation's most successful companies within the economy's most dynamic segment—independent, entrepreneurial businesses. Rankings are based on percentage revenue growth from 2021 to 2024, and RAM Technologies was honored for its exceptional growth and innovation. "It's an honor to once again be recognized on the Inc. 5000 list," said Robert Tulio, CEO of RAM Technologies. "Our growth is the result of a clear mission to equip government-sponsored health plans with software and services to operate efficiently and put members at the center of every decision. This achievement reflects the impact we're making in the healthcare industry, and our team's focus on innovation and quality." The company's sustained growth has been fueled by expanding relationships with health plans nationwide, a commitment to exceptional client service and the ability to provide BPaaS solutions that enhance outcomes for clients. RAM Technologies specializes in delivering purpose-built solutions for government-sponsored health plans. The company's core platform, HEALTHsuite Advantage, gives health plans added flexibility through the choice of SaaS and BPaaS deployment models. By combining software with expert implementation and support, RAM helps health plans reduce costs, streamline operations and improve member experiences. "Our solutions give health plans tools to operate more efficiently, deliver a better experience for members and ensure compliance with regulatory requirements," said Tulio. "We're proud to have achieved sustained growth in such a competitive market, and we remain focused on delivering solutions to help our clients succeed." For the full list, company profiles, and a searchable database by industry and location, visit: About RAM Technologies RAM Technologies is a leading provider of enterprise solutions for government-sponsored healthcare payers. For over 44 years RAM Technologies has led the way in the creation of comprehensive, end-to-end SaaS and BPaaS solutions for health plans administering Medicare Advantage, Managed Medicaid and Special Needs plans. Our deep understanding of Medicare and Medicaid guarantees seamless integration and operational ease, allowing health plan staff to focus on what matters most. To learn more about RAM Technologies visit View source version on Contacts Media Contact Robert Meyer, RAM Technologies, Inc., rmeyer@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
